Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Atypical Vs Conventional Antipsychotics
NCT00237861Phase 4Completed
- Sponsor
- Yale University
- Primary completion
- Dec 2002
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of risperidone, olanzapine and quetiapine in schizophrenia (2 arms), sponsored by Yale University. Primary endpoints: Positive and Negative Syndrome Scale and Retention in treatment at 1 year. Status: completed.
02
Drugs
risperidoneolanzapinequetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00237861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237861.